Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 USD | -2.42% | -6.70% | -83.74% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.74% | 141M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- RAPT Therapeutics Shares Jump After Positive Data From Phase 2 Trial of FLX475 Plus Pembrolizumab in Cancer Patients